A5065094159- Cancer Immunotherapy and Biomarkers
- Multiple Myeloma Research and Treatments
- Sarcoma Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Lymphoma Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Radiomics and Machine Learning in Medical Imaging
- CAR-T cell therapy research
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis
- Protein Degradation and Inhibitors
- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Colorectal and Anal Carcinomas
- Cardiac tumors and thrombi
- Glycosylation and Glycoproteins Research
- Carcinogens and Genotoxicity Assessment
- Cancer Diagnosis and Treatment
- Gastrointestinal Tumor Research and Treatment
- Immune Cell Function and Interaction
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Prostate Cancer Treatment and Research
- Advanced Breast Cancer Therapies
- Acute Lymphoblastic Leukemia research
- Cell Adhesion Molecules Research
Cancer Research And Biostatistics
2010-2022
Mallinckrodt (United States)
2016
Cleveland Clinic
2016
Sarcoma Alliance for Research through Collaboration
2016
Columbia University Irving Medical Center
2016
University of Michigan
2016
Seoul St. Mary's Hospital
2016
Catholic University of Korea
2016
The University of Texas MD Anderson Cancer Center
2016
Washington University in St. Louis
2008-2016
Soft-tissue sarcomas represent a heterogeneous group of cancer, with more than 50 histological subtypes1,2. The clinical presentation patients different subtypes is often atypical, and responses to therapies such as immune checkpoint blockade vary widely3,4. To explain this variability, here we study gene expression profiles in 608 tumours across soft-tissue sarcoma. We establish an immune-based classification on the basis composition tumour microenvironment identify five distinct...
Summary Total therapy 3 incorporated bortezomib into a melphalan‐based tandem transplant regimen for 303 newly diagnosed patients with myeloma. Induction chemotherapy prior to and consolidation after transplants each consisted of two cycles VTD‐PACE (bortezomib, thalidomide, dexamethasone 4‐d continuous infusions cis‐platin, doxorubicin, cyclophosphamide, etoposide); 3‐year maintenance comprised monthly VTD in the first TD remaining years. The median age was 59 years (age >64 years, 28%)....
PURPOSE SARC024 is a phase II clinical trial of the multikinase inhibitor regorafenib in specific sarcoma subtypes, including advanced osteosarcoma. We hypothesized that would improve progression-free survival (PFS) patients with and report results osteosarcoma cohort. PATIENTS AND METHODS This enrolled progressive metastatic measurable disease by RECIST who had received at least one prior line therapy. Patients were randomly assigned ratio to or placebo. Crossover was allowed time...
Abstract Purpose: We recently reported a 17.5% objective RECIST 1.1 response rate in phase II study of pembrolizumab patients with advanced sarcoma (SARC028). The majority responses occurred undifferentiated pleomorphic (UPS) and dedifferentiated liposarcoma (DDLPS). sought to determine whether we can identify immune features that correlate clinical outcomes from tumor tissues obtained pre- on-treatment. Patients Methods: Pretreatment (n = 78) 8-week on-treatment 68) biopsies were stained...
BACKGROUND Insulin‐like growth factor‐1 receptor (IGF‐1R) is implicated in the pathogenesis of rhabdomyosarcoma (RMS), osteosarcoma (OS), and synovial sarcoma (SS). The authors conducted a multi‐institutional phase 2 trial monoclonal antibody R1507 patients with various subtypes recurrent or refractory sarcomas. METHODS Eligibility criteria included age ≥2 years diagnosis RMS, OS, SS, other soft tissue Patients received weekly dose 9 mg/kg intravenously. primary endpoint was best objective...
Summary Total Therapy 1, the first tandem autotransplant trial for newly diagnosed patients with multiple myeloma, was designed to increase frequency of complete response (CR) and thereby extend survival. With a median follow‐up 12 years, 62 231 initially enrolled are alive (17% at 15 years); 31 remain event free (7% years) including 16 94 (41%) that achieved CR. Currently less frequently had cytogenetic abnormalities (CAs) baseline ( P = 0·002), postenrolment < 0·001) relapse 0·004);...
To assess the impact of age on outcome and to analyze projected years life lost in patients with multiple myeloma.Ten thousand five hundred forty-nine were evaluated; 6,996 treated conventional chemotherapy, 3,553 high-dose therapy autologous stem-cell transplantation.Mean observed relative overall survival times entire cohort 3.7 3.9 years, respectively. Observed decreased steadily from 6.4 younger than 50 2.5 > or = 80 years. A similar decrease was noted for survival. Higher correlated...
BACKGROUND Alveolar soft part sarcoma (ASPS), chondrosarcoma (CS), chordoma, epithelioid sarcoma, and solitary fibrous tumor (SFT) are malignant tumors that relatively resistant to chemotherapy for which more effective drug therapy is needed. METHODS The 5 listed subtypes were enrolled into a single indolent cohort in phase 2 study of dasatinib using Bayesian continuous monitoring rule enrollment. primary objective was estimate the 6‐month progression‐free survival (PFS) rate according Choi...
11015 Background: Immune checkpoint inhibitors have demonstrated activity in multiple tumor types but their soft tissue sarcomas remains limited. In the multicenter phase II study, SARC028, anti-PD-1 antibody, P objective responses that were largely restricted to UPS and LPS subtypes. We now report outcomes from 2 expansion cohorts of SARC 028 advanced LPS. Methods: To further confirm clinical LPS, we enrolled an additional 30 pts each for a total 40 pts. Primary endpoint was...
Prostate cancer (PCa) becomes resistant to androgen ablation through adaptive upregulation of the receptor in response low-testosterone microenvironment. Bipolar therapy (BAT), defined as rapid cycling between high and low serum testosterone, disrupts this regulation castration-resistant PCa (CRPC).
Regorafenib is one of several FDA-approved cancer therapies targeting multiple tyrosine kinases. However, there are few subtype-specific data regarding kinase inhibitor activity in sarcomas. We report results a single arm, phase II trial regorafenib advanced Ewing family sarcomas.Patients with metastatic sarcomas (age ≥ 18, ECOG 0-2, good organ function) who had received at least line therapy and experienced progression within 6 months registration were eligible. Prior inhibitors not...
A number of studies have shown possible associations between occupational exposures, particularly solvents, and lymphomas. The present investigation aimed to evaluate the association exposure solvents lymphomas (Hodgkin non-Hodgkin) in a large population-based, multicenter, case-control study Italy.All newly diagnosed cases malignant lymphoma men women age 20 74 years 1991-1993 were identified 8 areas Italy. control group was formed by random sample general population under stratified sex...
257 Background: The Hh pathway is overexpressed in PDA tumors. Pre-clinically, inhibitors have demonstrated a reduction pancreatic cancer stem cells (pCSC) and stroma. Vismodegib, an oral small-molecule antagonist of the pathway, has previously been safely combined with Gemcitabine chemotherapy. Methods: Pts untreated, metastatic were treated (1000 mg/m 2 ) + nab-P (125 on days 1, 8 15 28 cycle. Vismodegib (150mg PO daily) was started second All drugs continued until disease progression or...
Abstract Background The etiology of non‐Hodgkin's lymphoma (NHL) and leukemia is still largely unknown, but exposure to chemicals, in particular pesticides, has been suggested be a risk factor. Methods A large population‐based case‐control study was conducted Italy with the aim investigating associations between pesticide NHL, solvents leukemia. Data presented this article refer 1,575 interviewed cases 1,232 controls nine agricultural areas. Results Exposure nitro‐derivatives phenylimides...
Abstract Background Many biological and chemical agents have the capacity to alter way immune system functions in human animals. This study evaluates immunotoxicity of 20 substances used widely work environments. Methods A systematic literature search on chemicals was performed. The first step review testing schemes adopted for establishing humans. second consisted providing a documentation that are environment, by building tables each interest (benzene, trichloroethylene, PAHs, crystalline...
11008 Background: SARC028 is the first multicenter Phase II study of P monotherapy in patients (pts) with STS and BS. Designed to detect clinical efficacy signals multiple histologies, collected blood & tissue samples on all pts. We report extended follow-up in-depth biomarker correlates response. Methods: The primary endpoint was objective response rate (ORR) by RECIST 1.1. Secondary endpoints were safety, 12 wk progression-free survival (PFS), overall (OS). arm had 10 pts each 4...
11005 Background: Pazopanib is approved for soft tissue sarcoma pts after failure of other therapy, but there are few subtype-specific data regarding kinase inhibitor activity. We report on a single arm, phase II trial REGO in advanced EWS. Methods: EWS (age > 18, ECOG 0-2, good organ function) who had at least 1 line therapy and PD within 6 mo were eligible. Prior oral inhibitors not allowed. Initial dose was 160 mg PO QD x21 q28d. Dose reductions employed toxicity AEs. The primary...
<h3>Importance</h3> Gastrointestinal stromal tumors (GISTs) are life-threatening when metastatic or not amenable to surgical removal. In a few patients with advanced GISTs refractory imatinib mesylate, treatment sunitinib malate followed by regorafenib provides tumor control; however, additional active treatments needed for most patients. <h3>Objective</h3> To evaluate the 6-month progression-free survival (PFS), objective response, and overall rates in treated dasatinib. <h3>Design,...
The aim of this study was to assess the prognostic and predictive value early quantitative <sup>18</sup>F-FDG PET monitor therapy with an antibody insulinlike growth factor 1 receptor (IGF-1R antibody) in patients Ewing sarcoma family tumors (ESFT). <b>Methods:</b><sup>18</sup>F-FDG images at baseline approximately 9 d after initiation IGF-1R 115 refractory or relapsed ESFT were prospectively obtained as part Sarcoma Alliance for Research through Collaboration trial. Responses centrally...